Boehringer Ingelheim R&D Spend: Human Pharma + Animal Health (Annual)
2020-2024
Updated at 2026-Q2
Boehringer Ingelheim Survodutide: SYNCHRONIZE + LIVERAGE Phase 3 Design
| Trial / Phase | Indication / Design | Primary Endpoint + Readout Window |
|---|---|---|
| Phase 1 SAD/MAD | Healthy volunteers + obesity cohort | 2017-2019 readouts; demonstrated dose-related pharmacokinetics + initial weight reduction; supported Phase 2 advancement |
| Phase 2 obesity (46 weeks) | Obesity Phase 2b | Mar 2023 topline: up to ~18.7% mean weight loss at 46 weeks at the 4.8mg weekly high dose vs ~2.0% placebo; GI tolerability comparable to other dual incretins; supports Phase 3 advancement |
| Phase 2 MASH biopsy (NEJM, 48 weeks) | MASH Phase 2b; 293 patients, fibrosis F1-F3 | NEJM June 7, 2024: dose-related improvement in MASH without worsening of fibrosis across 2.4/4.8/6.0mg, statistically superior to placebo (up to ~83% at the 6.0mg dose vs ~18% placebo); fibrosis improvement up to ~64.5% as a key secondary; supported the LIVERAGE Phase 3 program |
| SYNCHRONIZE-1 (Phase 3 obesity, registrational) | Obesity without T2D; ~725 patients | Primary endpoint weight loss at 76 weeks; April 2026 topline: up to 16.6% mean weight loss vs 3.2% placebo at 76 weeks; supports EU + FDA filing pathway |
| SYNCHRONIZE-2 (Phase 3 obesity in type 2 diabetes) | Obesity/overweight with type 2 diabetes | Phase 3 registrational trial; weight-loss primary endpoint in people with obesity and T2D; parallel pathway alongside SYNCHRONIZE-1 |
| SYNCHRONIZE-CVOT (cardiovascular outcomes) | Phase 3 cardiovascular outcomes | Long-duration cardiovascular outcomes trial supporting a CV-risk-reduction labeling claim; supports premium positioning vs semaglutide + tirzepatide; long-duration readout |
| LIVERAGE (Phase 3 MASH, F2-F3) | F2-F3 MASH; histology endpoints | Phase 3 MASH trial in fibrosis stages F2-F3; MASH resolution + fibrosis improvement at 52 weeks, with long-term outcomes follow-on; competing with Rezdiffra (approved March 2024), semaglutide (MASH approval August 2025), and efruxifermin (Novo/Akero) |
| LIVERAGE-Cirrhosis (Phase 3 MASH, F4) | F4 compensated cirrhosis | Phase 3 MASH trial in compensated cirrhosis (fibrosis stage F4); evaluates fibrosis and long-term clinical outcomes in the highest-fibrosis subset |
| Zealand Pharma partnership economics | Royalty + milestone obligations | Boehringer pays Zealand royalties on net commercial sales plus development, regulatory, and commercial-launch milestones per the 2011 collaboration; the royalty rate is undisclosed (analyst estimates ~10-15% on net sales) |
| Boehringer obesity-franchise allocation | R&D + capital allocation | Boehringer Ingelheim does not disclose Human Pharma R&D at the franchise level; survodutide is its single named obesity + MASH asset. Estimated cumulative R&D investment is ~1-2 billion EUR through 2025 based on Phase 1-3 trial costs + manufacturing build-out; supports its positioning as the only top-10 Big Pharma without a public listing competing in the GLP-1 space |
| Editorial. Why survodutide matters | Strategic context | Survodutide is among the most-advanced glucagon/GLP-1 dual agonists globally and the only Big Pharma asset in this mechanism class. Its Phase 2 obesity result (~18.7% at 46 weeks) and the SYNCHRONIZE-1 Phase 3 result (16.6% at 76 weeks) position Boehringer as a credible #3 Big Pharma incretin franchise behind LLY + NVO. The MASH indication is strategically important: survodutide could give Boehringer both obesity + MASH labels for a single asset |
Updated at 2026-Q2
Boehringer Ingelheim Cumulative Payments to Zealand Pharma (Survodutide Partnership)
2011-2024
Cumulative BI payments to Zealand (EUR millions, estimated)
Updated at 2026-Q2
